Allan R. Tenorio - Concepedia

Author

Allan R. Tenorio

Also Known As

A. R. Tenorio, A. Romero-García Tenorio, A.R. Méndez Tenorio, Ailton TENÓRIO, Allan R Tenorio, Allan R. Tenorio, Allan Tenorio, Allan R. Tenorio, Chan, Ellen S., Eron, Joseph J.

Publications

4.1K

Citations

H-Index

Concepts

All Affiliations

Rush University Medical Center ViiV Healthcare (United Kingdom)National Institute of Allergy and Infectious Diseases Triangle GlaxoSmithKline (United Kingdom)

About

Allan R. Tenorio is an author at Rush University Medical Center specializing in medicine, hiv, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	1.3K
2	Public Health	2	2	382
3	Health Sciences	1	1	210
4	Nursing	1	1	11
5	Allergy	1	1	502

Allan R. Tenorio

Publications

3.8K

Citations

H-Index

Page 1

	Year	Citations
Soluble Markers of Inflammation and Coagulation but Not T-Cell Activation Predict Non–AIDS-Defining Morbid Events During Suppressive Antiretroviral Treatment Allan R. Tenorio, Yu Zheng, Ronald J. Bosch, The Journal of Infectious Diseases	2014	521
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials Emma Guttman‐Yassky, Henrique D. Teixeira, Eric L. Simpson, The Lancet AllergyUpadacitinib Versus PlaceboAtopic DermatitisAllergy MedicineClinical Trials	2021	502
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials Pedro Cahn, Juan Sierra Madero, José Ramón Arribas, The Lancet Hiv/aids CounsellingTreatment And PreventionWeek 48Clinical EpidemiologyClinical Trials	2018	371
IL-7 administration drives T cell–cycle entry and expansion in HIV-1 infection Irini Sereti, Richard M. Dunham, John Spritzler, Blood	2009	331
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study Jean van Wyk, Faïza Ajana, Fiona Bisshop, Clinical Infectious Diseases	2020	257
Effectiveness of Gloves in the Prevention of Hand Carriage of Vancomycin-Resistant Enterococcus Species by Health Care Workers after Patient Care Allan R. Tenorio, Sheila Badri, Nishi Sahgal, Clinical Infectious Diseases Hand CarriageAntimicrobial SusceptibilityHealth SciencesAntibioticsAntimicrobial Stewardship	2001	210
Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials Pedro Cahn, Juan Sierra Madero, José Ramón Arribas, JAIDS Journal of Acquired Immune Deficiency Syndromes	2019	201
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis Eric L. Simpson, Kim Papp, Andrew Blauvelt, JAMA Dermatology	2022	189
Determinants of CD4<sup>+</sup>T Cell Recovery during Suppressive Antiretroviral Therapy: Association of Immune Activation, T Cell Maturation Markers, and Cellular HIV‐1 DNA Miguel Goicoechea, Davey M. Smith, Lin Liu, The Journal of Infectious Diseases	2006	111
Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial Kelly E. Dooley, Richard Kaplan, Noluthando Mwelase, Clinical Infectious Diseases	2019	108

Page 1